Expression of Interest (EOI): Test developers to inform about commercialized and in-development diagnostic tests for Meningococcus, Cholera, Yellow Fever, Typhoid, Measles and Rubella

BACKGROUND
Fit for purpose diagnostic tools are critical for countries’ ability to plan and implement targeted vaccination programmes, but there are limitations in the availability and use of such tools in low and middle income countries. Shortcomings in the availability of appropriate diagnostic tools for cholera, typhoid, meningococcus, measles, rubella and yellow fever are creating significant challenges for guiding vaccination programme efforts to prevent these diseases.

FIND is a global non-profit organization dedicated to accelerating the development, evaluation, and delivery of high-quality, affordable diagnostic tests for poverty-related diseases. Together with UNICEF and WHO, FIND participates as a core organization in the effort, supported by Gavi, the Vaccine Alliance, to improve the availability of fit-for-purpose diagnostic tests to make use of targeted vaccines more effective, efficient, equitable.

This expression of interest (EOI) is issued as part of FIND’s landscaping activities to identify manufacturers commercializing or developing a diagnostic test for Meningococcus, Cholera, Yellow Fever, Typhoid, Measles or Rubella.

BENEFITS TO MANUFACTURERS
• All manufacturers who submit their test information through this FIND EOI will be contacted for further discussion on their product and development pipeline. Submitters will also automatically be informed when WHO issues requests for expressions of interest in the evaluations of test kits for the specific diseases. These evaluations will cover test kits’ performance and manufacturing quality assurance. In 2023, a series of requests for EOs on test kit evaluations are expected for yellow fever, meningococcus, cholera, measles and typhoid. A request for EOs on rubella test kit evaluations may be issued in 2024. Other EOs may be issued in the future for these diseases. These WHO evaluations will be conducted through either the WHO Prequalification (PQ) process or WHO Expert Review Panels for Diagnostic Tests (ERPDs). Test kits that receive positive assessments from either WHO PQ or ERPD are eligible for procurement by a variety of international organizations and are more attractive for procurement by governments and other buyers in low and middle income countries.
• Upon agreement with the manufacturers/submitters, information about the tests will be published on the FIND website in our Test Directory to inform the global health community about available products. Examples of Test Directories listing diagnostics products for other disease areas can be found following these links (Covid-19, Monkey Pox, Ebola, Neglected Tropical Diseases).

CONFIDENTIALITY
FIND acknowledges that the information received from Applicants under the EOI may be of a confidential nature. FIND shall use the same degree of care with Applicant’s confidential information as it uses to protect its own confidential information. If required, FIND can sign a CDA with interested...
Applicants prior to proposal submission. FIND will communicate the confidential information only to its employees, independent contractors, institutional donors and other financial sponsors, legal, financial, scientific or technical advisors (together “Representatives”) who: (a) need to know such confidential information for FIND’s internal purposes, and (b) such Representative has previously agreed in writing to be bound by terms and conditions substantially similar to those contained in this EOI, including but not limited to confidentiality and non-use restrictions. Review of proposals will be carried out by an internal FIND team as well as a team of external experts (which may or may not include members of FIND’s independent Scientific Advisory Committee), all of whom are under confidentiality and are recused if found to have a potential conflict of interest (which they are obliged to disclose). Any specific questions concerning confidentiality should be addressed to the FIND team.

**HOW TO APPLY**

Submit proposals via the [FIND technology scouting submission web form](#).